The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Initial characterization of the toxicity and efficacy of elacytarabine (CP-4055), a novel antileukemic agent, using a multidimensional exposure-response relationship model.
Murray P Ducharme
Consultant or Advisory Role - Caavis Pharma
Steinar Hagen
Employment or Leadership Position - Clavis Pharma
Stock Ownership - Clavis Pharma
Petter-Arnt Hals
Employment or Leadership Position - Clavis Pharma
Tove Flem Jacobsen
Employment or Leadership Position - Clavis Pharma
Stock Ownership - Clavis Pharma
Francis J. Giles
Consultant or Advisory Role - Clavis Pharma
Research Funding - Clavis Pharma
Expert Testimony - Clavis Pharma
Other Remuneration - Clavis Pharma
Susan Mary O'Brien
Research Funding - Clavis Pharma
Hubert Dirven
Employment or Leadership Position - Caavis Pharma
Colucci Phillipe
Consultant or Advisory Role - Clavis Pharma (U)
Corinne Seng Yue
No relevant relationships to disclose